Share this page!

Albert Bourla Profile picture
Twitter logo
Aug 15 • 3 tweets • 1 min read
I would like to let you know that I have tested positive for #COVID19. I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid.
We have come so far in our efforts to battle this disease that I am confident I will have a speedy recovery. I am incredibly grateful for the tireless efforts of my Pfizer colleagues who worked to make vaccines and treatments available for me and people around the world.
Paxlovid is not approved, but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients 12+, weighing at least 40 kg, with positive results of SARS-CoV-2 viral testing. See safety info: COVID19oralRx.com.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Albert Bourla

Albert Bourla Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertBourla

Albert Bourla Profile picture
Apr 1, 2021
Excited to share that updated analysis from our Phase 3 study with BioNTech also showed that our COVID-19 vaccine was 100% effective in preventing #COVID19 cases in South Africa. 100%! pfizer.com/news/press-rel…
800 participants enrolled in South Africa with 0 cases of #COVID19 observed in the vaccinated group. Of the cases observed the majority were confirmed to be of the B.1.351 lineage, the prevalent strain in South Africa.
These data support previous results from immunogenicity studies demonstrating a robust neutralizing antibody response to the B.1.351 variant.
Read 4 tweets
Albert Bourla Profile picture
Nov 18, 2020
Very happy to say that we have more good news to share. The final efficacy analysis of @Pfizer's Phase 3 study showed that our #COVID19 vaccine candidate met all of the study's primary efficacy endpoints: pfizer.com/news/press-rel…
Most notably, the vaccine candidate was shown to be 95% effective in helping prevent #COVID19 beginning 28 days after the first dose.
We also announced that the safety database required by the @US_FDA for Emergency Use Authorization (EUA) has been achieved.
Read 5 tweets
Albert Bourla Profile picture
Nov 16, 2020
Today marks a major milestone – Upjohn’s separation from @pfizer and the completion of the combination of Upjohn with @MylanNews to form @ViatrisInc: on.pfizer.com/3lCincT
From the bottom of my heart, I want to thank our Upjohn colleagues for their contributions over the years and dedication in helping us achieve this milestone. They have made our company stronger and helped us deliver meaningful value to patients around the world.
I know our Upjohn colleagues will deliver the same value for @ViatrisInc, which will combine best-in-class manufacturing, science experience and proven commercial capabilities to bring quality medicines to patients.
Read 4 tweets
Albert Bourla Profile picture
Sep 13, 2020
Thank you @margbrennan for the great #COVID19 discussion on @facethenation this morning. Our decision to expand the Phase 3 trial would allow us to further increase population diversity as well as generate even more safety and efficacy data.
Volunteers from all over the country have raised their hands to participate, and now we want to expand to ensure we include more vulnerable populations.
We chose to fund our program without accepting taxpayer money so we could liberate our scientists from bureaucracy and allow them to focus solely on the scientific challenges.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(